Nadofaragene Firadenovec Results in uMRD-Negative Status in NMBIC
uMRD-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in NMIBC
Surgery/Immunotherapy Safety Data Reflect “Exciting Era” for RCC Treatment
Surgery after neoadjuvant immune checkpoint inhibitor therapy for renal cell carcinoma is safe even in challenging surgical cases, according to Jason Scovell, MD.